This volume brings together the key research issues in clinical and laboratory science relating to metastasis in prostate cancer. It is especially suitable for those in the field, whether physicians and/or scientists, and whether in active research or in training, who wish to broaden their understanding, with regard to their own discipline, and also to another. It is also a resource for those whose research is in metastasis, but in diseases other than prostate cancer. The intention of this volume is to help to empower those who seek to further exploit the potential for translational research in this field.Written by a team of internationally recognised experts, coverage ranges from the most fundamental aspects of the molecular biology of metastasis, to the patient in the clinic. The therapeutic approaches range from conventional drug design to immunogene therapy.

Over the past two decades, there has been a tremendous increase in our understa- ing of ubiquitination and proteasome degradation. As the editors, we thank Springer Publishing for allowing us to organize this collection of reviews on the ubiquit- proteasome system, oncogenesis, and cancer therapy. We asked our colleagues, who are experts in the field, to provide an overview of their research and recent progress. Each chapter covers a broad range of topics that include defects in ubiquitination identified in specific tumors to new directions to treat cancer. In the Introduction, Rati Verma gives the background of our current understanding of the proteasome. A general overview of ubiquitin ligases and cancer is provided by Angelika Burger and Arun Seth. Patricia McChesney and Gary Kupfer discuss the role of the Fanconi anemia/BRCA1 pathways in breast cancer and potential targets for therapy. Defects in the tumor suppressor, von Hippel-Lindau E3 ligase, and the role of this protein complex are discussed by William Kim and William Kaelin. Kyung-bo Kim and colleagues describe the development of novel proteasome inhibitors to treat cancer patients. Progress in our understanding of deubiquitinating enzymes is summarized by Massimo Loda and his colleagues. Finally, Agustin Rodriguez-Gonzalez and Kathleen Sakamoto discuss an approach to recruit cancer-causing proteins to ub- uitin ligases through a chimeric molecule known as protacs.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, geni tourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

In the approach to the analysis of disease, including, of course, cancer, two major thrusts may be distinguished. These may be referred to, in shorthand, as agents and processes: the causative agents (chemical, microbial, physical, environmental, and psychosocial) and the organismic processes, initiated and furthered by the agents, culminating in observable pathology (at the macromolecular, cytological, histological, organ function, locomotor, and behavioral levels). The past 25 years, since the appearance of the first volume of the predecessor series (1) authored by the Editors of this present volume, have seen an impressive number of studies on chemicals (and other agents) as etiologic factors in the induction of cancer. The major emphasis has been on the discovery of many chemical carcinogens of widely different structures, their metabolism by various tissues and cells, and, in turn, their molecular-biochemical effects on the cells. This rapidly expanded body of information, as effectively covered in the predecessor volumes, is an excellent entree to the second half of the overall problem of chemical carcinogenesis, the processes. The active agents trigger a large array of molecular-biochemical alterations to which the target cells, target tissues, and target organisms respond in many select and common ways. This second major aspect of the induction of cancer by chemicals (and by other agents)- the sequence of cellular and tissue changes clearly relevant to cancer-remains the challenge for the future.

Since the first concepts of gene therapy were formulated, the hemopoietic system has been considered the most natural first target tissue for genetic manipulation. The reasons for this include the fact that a very large number of inherited disorders (including some of the most common disorders, such as the hemoglobinopathies) are disorders of the hemopoietic system, and the large amount of experience in hematopoietic transplantation biology. The consequence of this resulted in the first clinical trial of gene therapy in 1989, where two children suffering from severe combined immune deficiency (ADA-SCID) were transplanted with T-cells express ing adenosine deaminase (the defective enzyme in patients with this disorder). The partial success of this treatment was perhaps responsible for undue optimism among those proposing other gene therapy treatments within the hematopoietic system, and it has since become clear that there are a number of technical and biological difficulties to overcome before hematopoietic gene therapy becomes a mainstream therapeutic strategy. The chapters in this book evaluate the need for gene therapy in the hematopoietic system, discuss how efficient gene transfer and expression can be achieved in the target cells, highlight areas of difficulty to be addressed, and examine a number of potential applications of the gene therapy approach. The book begins with a chapter by Testa and colleagues, discussing the various sources of hematopoietic cells for both transplantation and gene therapy."

In recent years excellent progress has been the study of these disorders in the future. made in the development of improved Recently freeze fracture techniques have cytochemical and ultrastructural tech- also been employed in the study of normal niques for electron microscopy in hematol- and leukemic lymphocytes and much new ogy and in particular in leukemia and information concerning leukemic cell lymphoma. Subtypes of these disorders, membranes may be obtained from the use which are essentially classified according to of this technique in the future. cell phenotype and the degree of matura- The purpose of this book is to demon- tion, can be well defined today using a strate the utility of these techniques in combination of immunological methods, defining leukemic cell types and to illus- light microscopy, cytochemistry, and elec- trate the potential of some of the newer tron microscopy. Ultrastructural cyto- ultrastructural methods, including trans- chemistry is now utilized routinely in mission and scanning immuno electron leukemia in most major centers today and microscopy, SEM cytochemistry, and can also be performed using scanning elec- freeze fracture techniques, in the study of tron microscopy (SEM), as described in leukemia. Advances in cytochemical tech- this book. Immuno electron microscopy niques and their use in the definition of used with or without simultaneous ultra- nonlymphoid cells and in the classification structural cytochemistry can also be em- of lymphoid subtypes are clearly demon- ployed in the accurate classification of strated in this book.

This new work on oral complications of cancer chemotherapy is edited by two dentists who have made pioneering contributions in this previously neglected area. Their efforts have established the invaluable role of the dentist in oncologic research and cancer patient management. The editors have collected nine chapters that will be of interest to dentists and dental hygienists, oncology nurses, and all physicians treating cancer patients with chemo therapeutic agents. Background chapters on oral complications of cancer chemotherapy, the pharmacology of chemotherapeutic agents, and principles of infection management and prevention set the stage for more specific chapters focusing on prevention and treatment of chemotherapy induced oral and dental disorders. Valuable contributions to the supportive care of the cancer patient are contained in this book. A full comprehension of this book, coupled with an appreciation for advances in other areas of supportive care, such as antiemetic therapy and pain control, will allow all those involved in cancer treatment to be more successful. Peter H. Wiernik, M.D. Emil Frei, M.D."

The hybridoma technique for producing monoclonal antibodies developed by Drs. Kohler and Millstein in 1975 revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value, and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of Cancer Treatment and Research explores the current state of the art of immunoconjugate therapy of hematologic malignancies. The first chapter, authored by Drs. Rosen and Kuzel, reviews the current status of radioimmunotherapy of lymphoma. Results of clinical investigations utilizing radiolabeled immunoconjugates in B-cell lymphomas, T-cell lym- phomas, and Hodgkin's disease are discussed. In addition, obstacles to effective antibody therapy are highlighted and toxicities are summarized. Chapter 2, written by Drs. Sgouros and Scheinberg, critiques the treat- ment of leukemia with radiolabeled monoclonal antibodies. In this chapter, the unique features of leukemia that make it particularly suitable for radio- immunotherapy are discussed, an overview of selected clinical trials is presented, and a treatment planning approach to radioimmunotherapy in- corporating biologic and physical parameters is reviewed.

The fifth of the annual research conferences of the American Institute for Cancer Research was held September l-2, 1994, at the L'Enfant Plaza Hotel in Washington, DC. Appropriately, in view of current directions in research, the theme was "Diet and Cancer: Molecular Mechanisms of Interactions." This proceedings volume contains chapters from the platform presentations and abstracts from the poster session held on the end of the first day. The subtopics for the tl;rree sessions held were "Retinoids, Vitamins A and Din Cancer Prevention and Therapy," "Choline and Lipids: Signal Transduction, Gene Expression and Growth Regulation," and "Dietary Factors and Regulation of Oncogenes, Growth and Differentiation. " A general overview on vitamins A and D emphasized that A and D, in addition to their established roles in vision, reproduction, and bone mineral homeostasis, may play significant roles in regulating cell function. Vitamin A metabolites, trans-retinoic acid and 9-cis-retinoic acid, regulate growth and differentiation. Furthermore, vitamin A deprived animals were more susceptible to both spontaneous and carcinogen-induced tumors. Epidemiological studies showed a correlation between low A intake and higher incidences of certain types of human cancers. Conversely, all-trans retinoic acid is useful in treatment and control of certain types of cancer. Physiologically, Vitamin D is converted to the active form, l,25-dihydroxyvitamin D (VD). VD regulates hormone production and secretion, myocardial contractility, vascu 3 3 3 lar tone, and growth inhibition and differentiation."

A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcade (TM)) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitour inary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

Transferring hematopoietic stem cells and immune cells has continued to be a promising therapeutic alternative and a fascinating area of cell biology as well as a field of persistent procedural problems. This explains why substantial parts of basic research on cell growth and differentiation, immune tolerance and antitumor effects, gene transfer, minimal residual disease and supportive care have settled around clinical transplantation in hematology and oncology. This second volume updates the current role of allogeneic and autologous transplantation in leukemias, lymphomas and solid cancers, including controversial strategies and novel experimental approaches. Outstanding representatives of leading groups guarantee first-hand information and indicate how we can work and cooperate more effectively to the benefit of our patients.

The field of genito-urinary oncology is rapidly evolving at virtually every level. Significant advances have been made in our understanding of the molecular and cellular events which contribute to the generation of GU malignancies. At the same time, similar advances have been made in the clinical arena which have improved the diagnosis and treatment of urologic cancers. This volume attempts to summarize those advances which most impact us as clinicians, and has been divided into three sections. Section One, `Diagnostic advances: the use of molecular medicine in the diagnosis and prognosis of GU malignancies', details how epidemiologic studies and new molecular techniques are impacting our ability to diagnose and treat GU tumors. Section Two, `Surgical and radiation advances', details the recent major advances in the treatment of organ-confined cancers. Section Three, `Medical advances', addresses major issues in the treatment of metastatic disease. This volume will serve as a compendium of the advances, both at the basic science and clinical levels, which are currently impacting practicing oncologists and urologists.

There have been significant advances in the treatment of sarcomas in the past several years. Further, different clini cal treatment programs are being advocated in different areas including surgery alone, surgery with preoperative or post operative chemotherapy, surgery with different radiotherapy modalities, with each investigator espousing his own treat ment program. On the other side, there is the question of whether these treatment programs are offering better results or whether the natural history of sarcomas has changed. The International Symposium on Sarcomas was held at Innisbrook Resort, Tarpon Springs, Florida, October 8-10, 1987. This was the first international symposium to date involving all of the disciplines treating sarcomas including pathologists, orthopaedic surgeons, general surgeons, medical oncologists, pediatric oncologists, and radiation oncol ogists. The Symposium brought together a number of special ists working in the clinical field of sarcomas for a presen tation of their specific treatment programs and their results. The presentations were followed by panel discussions to stimulate educational debate as to the different forms of treatment for sarcomas and to formulate some conformity in control of disease, control of spread, and ultimate function for the patient. James R. Ryan, M.D."

In recent decades eicosanoids have been attracting an increasing amount of attention as a result of their important physiological roles in many areas of biology and medicine. The eicosanoids comprise the prostaglandins, thromboxanes and leukotrienes and are products of arachidonic acid, an essential polyunsaturated fatty acid stored in tissue phospholipids. Disturbances of eicosanoids and their metabolic products play a regulatory role in many types of cell injuries and diseases. One of the most exciting areas of eicosanoid research pinpoints their participation in the control of cell proliferation and differentiation. Eicosanoids form a link between different fields of research into such areas as cancer, inflammation and radiation-induced injury. This link provided the impetus for the development of the conference series of which the present volume represents the proceedings of the Second International Conference, held in Berlin in October 1991.

This book provides a comprehensive, highly readable overview of our current knowledge of the molecular pathology of basal cell and squamous cell carcinomas. The chapters present the newest findings in epidemiology, photocarcinogenesis, genetics, immunology and molecular pathology of these epithelial skin tumours. Topics include the importance of the hedgehog/patched/smoothened/GLI, p53, PDGF, or TGF-b signalling pathways as well as the relevance of papilloma virus infections, apoptosis, DNA-repair and telomerase.

A comprehensive state-of-the-art summary of breast cancer research and treatment by leading authorities. The book's many distinguished contributors illuminate the biology and genetics of breast cancer, including what is known about the hereditary breast cancer genes, BRCA1 and 2, the cutting-edge cytogenic approaches, and the biology of breast cancer metastasis. In addition, the authors describe current and future methods of breast cancer treatment in depth, and discuss environment and diet as risk factors for the disease. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics constitutes an excellent reference and resource for all those clinical and experimental oncologists, as well as genetic counselors nurses, who need to understand the latest developments in breast cancer biology, risk, and treatment.

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

Over one hundred contributions detail advances in the molecular and cellular biology of eicosanoid production, as well as their role in signal transduction. One of the most exciting developments explored within this collection of articles is the expression of the novel isoform of cyclooxygenase (cox-2), which may play a large role in the development of anti-inflammatory drugs.

As in CANCER CHEMOTHERAPY 1, this volume brings to the reader highlights in three different areas of cancer therapeutics: new concepts and models; drug classes; and clinical settings. Topics were chosen because of their timeliness or probable current impact in cancer treatment. Authors were selected on the basis of their ability to provide a critical overview of specific subjects and their involvement in original work. I shall review the aims of this second volume, and then elaborate on the scope of its con tents. The principal aim of the volumes on cancer chemotherapy in the' Cancer Treatment and Research' series, as stated in the preface to the first volume, is to assemble in a concentrated form selected ingredients of chemothera peutic progress. These ingredients are to include concepts in therapeutic strategy, pre-clinical studies, development of major classes of compounds, identificatlon of new directions and of landmarks of clinical progress. Thus we do not foresee overlap with series which provide an yearly update of chemotherapy in an encyclopedic manner, or reviews of cancer chemother apy. Unlike those publications, our volumes are not intended to seek a place in shelves as a reference manual. It is this Editor's hope that persons repre senting various biomedical disciplines will seek the' Cancer Treatment and Research' chemotherapy volumes to survey advances in the field at regular intervals.

This book provides an up-to-date comprehensive overview of the exciting new developments shaping the current and future practice of radiation oncology. Advances in treatment planning and delivery, in biological targeted therapies combined with radiation and in functional and molecular imaging are all covered in a single volume. All of these advances are discussed by leading experts in the field and with a critical evaluation of their clinical relevance throughout.

NA methylation has bewildered molecular biologists since Hotchkiss discovered it almost six decades ago (Hotchkiss RDJ. Biol Cem 1948; 175:315-332). The fact that the chemical structure of our D genome consists of two components that are covalently bound, the genetic information that is replicated by the DNA replication machinery ana DNA methylation that is maintainea by independent enzymatic machinery, has redictably stimulated the imagination and curiosity of generations of mo Edular biologists. An obvious question was whether DNA methylation was a bearer of additional information to the genetic information and what was the nature of this information? It was tempting to speculate that DNA me thylation applied some form of control over programming of the genome s expression profile. Once techniques to probe the methylation profile of whole genomes as well as specific genes became available, it became clear that DNA methylation patterns are gene and tissue specific and that patterns of gene expression correlate with patterns of methylation. DNA methylation pat terns emerged as the only component of the chemical structure of DNA that exhibited tissue and cell specificity. This data seemingly provided an attrac tively simple explanation for the longstanding dilemma of how could one identical genome manifest itself in so many different forms in multicellular organisms? The DNA methylation pattern has thus become the only known factor to confer upon DNA a unique cellular identity.

2009 Choice Outstanding Academic Title 2009 Association of American University Presses Award for Jacket Design The stories of 70 women living in the aftermath of breast cancer Chemo brain. Fatigue. Chronic pain. Insomnia. Depression. These are just a few of the ongoing, debilitating symptoms that plague some breast-cancer survivors long after their treatments have officially ended. While there are hundreds of books about breast cancer, ranging from practical medical advice to inspirational stories of survivors, what has been missing until now is testimony from the thousands of women who continue to struggle with persistent health problems. After the Cure is a compelling read filled with fascinating portraits of more than seventy women who are living with the aftermath of breast cancer. Emily K. Abel is one of these women. She and her colleague, Saskia K. Subramanian, whose mother died of cancer, interviewed more than seventy breast cancer survivors who have suffered from post-treatment symptoms. Having heard repeatedly that "the problems are all in your head," many don't know where to turn for help. The doctors who now refuse to validate their symptoms are often the very ones they depended on to provide life-saving treatments. Sometimes family members who provided essential support through months of chemotherapy and radiation don't believe them. Their work lives, already disrupted by both cancer and its treatment, are further undermined by the lingering symptoms. And every symptom serves as a constant reminder of the trauma of diagnosis, the ordeal of treatment, and the specter of recurrence. Most narratives about surviving breast cancer end with the conclusion of chemotherapy and radiation, painting stereotypical portraits of triumphantly healthy survivors, women who not only survive but emerge better and stronger than before. Here, at last, survivors step out of the shadows and speak compellingly about their "real" stories, giving voice to the complicated, often painful realities of life after the cure. This book received funding from the Susan G. Komen Foundation.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfor tunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung can cer, genitourinary cancer, pediatric oncology, etc. Second, by asking emi nent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."